Protective effect of CardiPro against doxorubicin-induced cardiotoxicity in mice.
The effect of CardiPro, a polyherbal formulation, with an antioxidant property, has been studied on doxorubicin (DXR)-induced cardiotoxicity in mice. CardiPro (150 mg/kg b.w., twice daily was administered orally for 7 weeks along with four equal injections (each containing 4.0 mg/kg b.w., DXR) intraperitoneally, once weekly (cumulative dose 16 mg/kg). After a 3-week post DXR treatment period, cardiotoxicity was assessed by noting mortality, volume of ascites, liver congestion, changes in heart weight, myocardial lipid peroxidation, antioxidant enzymes and histology of heart. DXR-treated animals showed higher mortality (50%) and more ascites. Myocardial SOD and glutathione peroxidase activity were decreased and lipid peroxidation was increased. Histology of heart of DXR-treated animals showed loss of myofibrils and focal cytoplasmic vacuolization. CardiPro significantly protected the mice from DXR-induced cardiotoxic effects as evidenced by lower mortality (25%), less ascites, myocardial lipid peroxidation, normalization of antioxidant enzymes and minimal damage to the heart histologically. Our data confirm the earlier reports that DXR cardiotoxicity is associated with the free radical-induced tissue damage. Administration of CardiPro, with an antioxidant property, protected the DXR-induced cardiotoxicity in mice.
Department of Clinical Pharmacology & Therapeutics, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, 500082, India.
I K
IK
Mohan
K V
KV
Kumar
M U R
MU
Naidu
M
M
Khan
C
C
Sundaram
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D000975:Antioxidants / Q000032:analysis; D001201:Ascites; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D002839:Chromans / Q000494:pharmacology; D004317:Doxorubicin / Q000633:toxicity*; D004338:Drug Combinations; D004798:Enzymes / Q000187:drug effects; D005260:Female; D006321:Heart / Q000187:drug effects; D015227:Lipid Peroxidation / Q000187:drug effects; D019684:Magnoliopsida / Q000737:chemistry*; D051379:Mice; D039281:Nyctaginaceae / Q000737:chemistry; D031339:Ocimum / Q000737:chemistry; D029842:Phyllanthus emblica / Q000737:chemistry; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D029766:Terminalia / Q000737:chemistry; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D018675:Toxicity Tests / Q000379:methods; D032341:Withania / Q000737:chemistry
D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D002839:Chromans; D004338:Drug Combinations; D004798:Enzymes; D010936:Plant Extracts; D017392:Thiobarbituric Acid Reactive Substances; D004317:Doxorubicin; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid